Noven at a Glance

(As of April 2011)
Core Business: Specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products.


Vivelle-Dot®,
the most prescribed transdermal estrogen therapy product in the U.S., developed and manufactured by Noven

Year of Incorporation: 1987
Locations:

Noven Pharmaceuticals, Inc.

Florida:
11960 SW 144th Street
Miami, FL 33186
Tel: 305-253-5099


New York:
Empire State Building
350 Fifth Avenue
37th Floor
New York, NY 10118
Tel: 212-682-4420

California:
2730 Loker Avenue W.
Carlsbad, CA 92010
Tel: 760-431-4670

President &
Chief Executive Officer:
Jeffrey F. Eisenberg
Vice President &
Chief Financial Officer:
Michael D. Price
Media, General Business
& Other Inquiries:
Joseph C. Jones
Vice President – Corporate Affairs
Tel: 305-253-1916
jjones@noven.com
Licensing and
Business Development
Inquiries Only
:
Patrick Gallagher
Vice President –
Business Development
Tel: 212-287-0968
pgallagher@noven.com
Affiliated Companies: Parent Company:
Noven is an indirect wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc.

Novogyne Pharmaceuticals –
a women’s health products company jointly owned by Noven and Novartis Pharmaceuticals Corporation

Noven Therapeutics, LLC –
Noven's specialty pharmaceuticals marketing and sales company
Employees: Over 650
Key Products:

Vivelle-Dot®
(estradiol transdermal system)
World’s Smallest Transdermal Estrogen Patch (U.S.)
Marketed by Novogyne Pharmaceuticals

CombiPatch®
(estradiol/norethindrone acetate)
Combination Estrogen/Progestogen Patch (U.S.)
Marketed by Novogyne Pharmaceuticals

Estradot®
(estradiol transdermal system)
World's Smallest Transdermal Estrogen Patch (Europe & elsewhere)
Marketed by Novartis

Estalis®
(estradiol/norethindrone acetate)
Combination Estrogen/Progestogen Patch (Europe & elsewhere)
Marketed by Novartis


Stavzor®
(valproic acid)
Delayed Release Capsules
Marketed by Noven Therapeutics, LLC


Pexeva®
(paroxetine mesylate)
Selective Serotonin Reuptake Inhibitor (SSRI)
Marketed by Noven Therapeutics, LLC


Lithobid®
(lithium carbonate)
Extended Release Lithium (U.S.)
Marketed by Noven Therapeutics, LLC


Daytrana®

(methylphenidate transdermal system)
Once-daily Transdermal Methylphenidate Patch (U.S.)
Marketed by Noven Therapeutics, LLC

Fentanyl Transdermal System
(fentanyl)
Extended Release Fentanyl Patch (U.S.)
Marketed by Apotex Corp.

Research & Development: A non-hormonal oral product (Mesafem™) in development for menopausal hot flashes, and a range of transdermal drug delivery systems in development for women's health, central nervous system disorders and other therapeutic areas, including transdermal development collaborations with Hisamitsu.
Patient, Physician
and Pharmacist Inquiries
Regarding
Stavzor
®,
Pexeva
® and Lithobid®:

Kendle International, Inc.
441 Vine Street
Suite 1200
Cincinnati, OH 45202
Attn: Safety Department
Tel: 800-455-8070


Patient, Physician
and Pharmacist Inquiries
Regarding, Vivelle-Dot
®
or CombiPatch®:

Customer Interaction Center
Novartis Pharmaceuticals Corporation
One Health Plaza
Building 122
East Hanover, NJ 07936
Tel: 888-669-6682
Fax: 973-781-3115
Click here for E-mail Contact

Patient, Physician
and Pharmacist Inquiries
Regarding Daytrana
®:

Daytrana® Information
11960 SW 144th Street
Miami, FL 33186
Tel: 877-567-7857

Patient, Physician
and Pharmacist Inquiries
Regarding Fentanyl
Transdermal System
:

Apotex Corp.
2400 North Commerce Parkway
Suite 400
Weston, FL 33326
Tel: 888-333-6127

Copyright © 2012 Noven Pharmaceuticals, Inc. All rights reserved.